Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

Summary

As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.

Eligibility

Inclusion Criteria:

* patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" .
* no drug contraindications .
* aged between 45 and 75 .
* committed to follow the research procedures, And cooperate with the •implementation of the whole process study .
* the patient understands the relevant treatment process .
* the patient has the ability to give informed consent .
* The patient had not recently taken any medication that affected observation.
* the subjects must meet all the inclusion criteria to be eligible to participate in the study .

Exclusion Criteria:

* mental illness .
* patients with malignant tumors.
* patients with other infectious diseases .
* patients with metabolic bone disease, diabetes and hyperthyroidism.
* patients who cannot actively cooperate in the treatment.
* hypocalcemia.

Conditions2

Browse More Trials